CA 102N

Drug Profile

CA 102N

Alternative Names: CA102N; HA-Nimesulide; Hyaluronic acid nimesulide-NH2 bioconjugate

Latest Information Update: 01 Jun 2016

Price : $50

At a glance

  • Originator Holy Stone Healthcare
  • Class Antineoplastics; Drug conjugates
  • Mechanism of Action CD44 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Colorectal cancer

Most Recent Events

  • 30 May 2016 Preclinical trials in Colorectal cancer in Taiwan (IV) before May 2016
  • 21 Apr 2015 Positive pharmacodynamics and adverse events data from in vitro and in vivo studies presented at the 106th Annual Meeting of the American Association for Cancer Research (AACR-2015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top